$58.19
▼ -0.2% Today
as of Jul 22, 16:51 ET
Last 30 days
Recent Press Releases & News
MBX Biosciences Appoints Steve Hoerter as CEO; Kent Hawryluk Steps Down
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy?
Overview
52-week range
$9.43
$46
100% of range
Avg surprise (last 3)
+18.3%
Avg reaction (last 2)
+4.2%
100% positive
Latest IV / EM
96%
EM ±21.9% · $60 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.51 | $-0.62 | +17.7% | +28.2% | +8.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.63 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.58 | $-0.77 | +24.7% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.71 | $-0.81 | +12.3% | — | +0.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-2.78 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-12.62 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-10.26 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-9.40 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.68 | -$0.58 | -17.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-27M | — | $-24M | $-22M | $-27M | — | $-20M | $-17M |
| Net income | $-24M | — | $-22M | $-19M | $-24M | — | $-18M | $-16M |
| EPS (diluted) | $-0.50 | — | $-0.63 | $-0.58 | $-0.71 | — | $-2.78 | $-12.62 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $45M | $75M | $223M | $40M | $30M | $49M | $133M | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $449M | $382M | $398M | $229M | $244M | $267M | $281M | — |
| Total assets | $453M | $385M | $400M | $232M | $246M | $269M | $282M | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $15M | $16M | $13M | $12M | $11M | $11M | $11M | — |
| Total equity | $438M | $369M | $388M | $219M | $235M | $257M | $271M | $-98M |